| | 
Part, Chapter, Paragraph
1 I, 2. 10. 3(7) | Freeman C, Soete L, Efendioglu U (1995): Diffusion
2 I, 2. 11 | Freeman C, Soete L, Efendioglu U (1995): Diffusion
3 I, 3. 4 | Prioux F (1993): L’infecondité en Europe, in
4 I, 3. 4 | Europe, in A. Blum e J. L. Rallu (eds) Démographie
5 I, 3. 4 | Paris, 231-251.~ ~Toulemon, L (1995): The Place of Children
6 II, 5. 2. 4 | existing definitions ( 5.2 mmol/l, 6.2, 6.5 or 7.8) and difficulties
7 II, 5. 2. 4 | total cholesterol in mmol/l and prevalence of hypercholesterolemia
8 II, 5. 2. 4 | total cholesterol (mmol/L) and BMI (Kg/m2 ) men and
9 II, 5. 2. 6 | A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby
10 II, 5. 2. 7 | S35-S40.~Giampaoli S, Palmieri L, Panico S et al (2006):
11 II, 5. 2. 7 | Lancet 335:675-87.~Palmieri L, Donfrancesco C, Giampaoli
12 II, 5. 2. 7 | Panico S, Vanuzzo D, Pilotto L, Cesana G, Ferrario M, Chiodini
13 II, 5. 2. 7 | 570.~Panico S, Palmieri L, Donfrancesco C, Vanuzzo
14 II, 5. 2. 7 | M, Mattiello A, Pilotto L, Sega R, Giampaoli S, Stamler
15 II, 5. 3. 9 | Allemani C, Ciccolallo L, Santaquilani M, Berrino
16 II, 5. 3. 9 | Gatta G, Micheli A, Mangone L, Kunkler I, and the EUROCARE-4
17 II, 5. 4. 1 | hyperglycaemia 11.1 mmol/l (200mg/dl) in a random sample
18 II, 5. 4. 1 | fasting plasma sample 7.0 mmol/l (126 mg/dl) and /or a postprandial
19 II, 5. 4. 1 | postprandial value 11.1 mmol/l. (Report WHO/IDF 2006).
20 II, 5. 4. 2 | total cholesterol>5 mmol/l~14~Percent of diabetic subjects
21 II, 5. 4. 2 | months with LDL>2.6 mmol/l (>3 mmol/l)~13~Percent of
22 II, 5. 4. 2 | LDL>2.6 mmol/l (>3 mmol/l)~13~Percent of diabetic
23 II, 5. 4. 2 | months with HDL<1.15 mmol/l (<1.0 mmol/l)~11~Percent
24 II, 5. 4. 2 | HDL<1.15 mmol/l (<1.0 mmol/l)~11~Percent of diabetic
25 II, 5. 4. 2 | triglycerides >2.3 mmol/l (>2.0 mmol/l)~12~Percent
26 II, 5. 4. 2 | triglycerides >2.3 mmol/l (>2.0 mmol/l)~12~Percent of diabetic
27 II, 5. 4. 2 | serum creatinine 400 mol/l~9~Annual incidence of amputations
28 II, 5. 4. 2 | equal or above 6.1 mmol/l and below 7.0 mmol/l (fasting
29 II, 5. 4. 2 | mmol/l and below 7.0 mmol/l (fasting plasma glucose
30 II, 5. 4. 2 | plasma glucose 6,1 mmol/l and <7,0 mmol/l).~Measurement
31 II, 5. 4. 2 | 6,1 mmol/l and <7,0 mmol/l).~Measurement of glycated
32 II, 5. 4. 2 | cholesterol level>5 mmol/l is an important indicator
33 II, 5. 4. 2 | cholesterol above 5 mmol/l.~Measurement of LDL cholesterol
34 II, 5. 4. 2 | cholesterol level >2.6 mmol/l is an important indicator
35 II, 5. 4. 2 | presenting a value above 2.6 mmol/l.~Measurement of HDL cholesterol
36 II, 5. 4. 2 | cholesterol level <1.0 mmol/l for men and <1.25 mmol/l
37 II, 5. 4. 2 | l for men and <1.25 mmol/l for women is measured as
38 II, 5. 4. 2 | 0 for men and 1.25 mmol/l for women.~Measurement of
39 II, 5. 4. 2 | Triglycerides level >2.3 mmol/l is an important indicator
40 II, 5. 4. 2 | cholesterol above 2.3 mmol/l.~Microalbuminuria should
41 II, 5. 4. 2 | above or equal to 400 umol/l (WHO).~The annual incidence
42 II, 5. 4. 3 | cholesterol level>5 mmol/l. In EUCID databases this
43 II, 5. 4. 3 | cholesterol level >2.6 mmol/l. Crude percentages published
44 II, 5. 4. 3 | cholesterol level <1.0 mmol/l for men and <1.25 mmol/l
45 II, 5. 4. 3 | l for men and <1.25 mmol/l for women. Crude percentages
46 II, 5. 4. 3 | Triglycerides level >2.3 mmol/l. In EUCID databases this
47 II, 5. 4. 8 | Armesto SG, Lapetra ML, Wei L, Kelley E and the Members
48 II, 5. 4. 8 | 2000), Marke LA, Nystrom L, Wall S, Ostman J., Excess
49 II, 5. 5.Int(18)| M, Tsuboi K, Dennerstein L.(2004): Prevalence of eating
50 II, 5. 5. 3 | 437-52.~Carney CP, Jones L, Woolson RF (2006): Medical
51 II, 5. 5. 3 | Holt RI, Bushe C, Citrome L (2005): Diabetes and schizophrenia
52 II, 5. 5. 3 | T, Suvisaari J, Peltonen L, Lonnqvist J (1997): Schizophrenia
53 II, 5. 5. 3 | Research Team (PORT) Project. L Amer Acad Psychoanalysis
54 II, 5. 5. 3 | T, Mackeprang T, Hansson L, Werdelin G, Karlsson H,
55 II, 5. 5. 3 | Osservatorio Regionale per l’Epilessia, 1996). On this
56 II, 5. 5. 3 | Behav 1:S9-S14.~Forsgren L, Bucht G, Erksson S, Bergmark
57 II, 5. 5. 3 | Bucht G, Erksson S, Bergmark L (1996): Incidence and clinical
58 II, 5. 5. 3 | Epilepsia 37:224-229.~Forsgren L (2004): Epidemiology and
59 II, 5. 5. 3 | Science; p. 21-42.~Forsgren L, Beghi E, Oun A, Sillanpaa
60 II, 5. 5. 3 | 1409.~Lindsten H, Nystrom L, Forsgren L (2000): Mortality
61 II, 5. 5. 3 | Lindsten H, Nystrom L, Forsgren L (2000): Mortality risk in
62 II, 5. 5. 3 | H, Stenlund, H, Forsgren L (2001): Remission of seizures
63 II, 5. 5. 3 | Psychiatry 69:13-17.~Nashef L, Fish DR, Garner S, et al (
64 II, 5. 5. 3 | Epilepsia 36:1187-1194.~Nashef L, Walker F, Allen P, et al (
65 II, 5. 5. 3 | Psychiatry 60:297-300.~Nilsson L, Tomson T, Farahmand BY,
66 II, 5. 5. 3 | Epilepsia 38:1062-1068.~Nilsson L, Ahlbom A, Farahmand BY,
67 II, 5. 5. 3 | Epilepsia 43:644-651.~Nilsson L, Ahlbom A, Farahmand BY,
68 II, 5. 5. 3 | Osservatorio Regionale per l’Epilessia (1996): ILAE classification
69 II, 5. 5. 3 | Pazzaglia P, Frank-Pazzaglia L (1976): Record in grade
70 II, 5. 5. 3 | 1007.~Sidenvall R, Forsgren L, Blomquist HK, Heijbel J (
71 II, 5. 5. 3 | 65.~Sidenvall R, Forsgren L, Heijbel J (1996): Prevalence
72 II, 5. 5. 3 | 45: 667-672.~Vignatelli L, Tonon C, D’Alessandro R,
73 II, 5. 5. 3 | LICE~Lega Italiana contro l’Epilessia~NICE~National
74 II, 5. 5. 3 | 234.~Becus T, Popoviciu L (1994): Epidemiologic survey
75 II, 5. 5. 3 | Benito-Léon J, Martín E, Vela L et al (1998): Multiple sclerosis
76 II, 5. 5. 3 | D, Kmetska K, Jordanova L, Topalov N (1997): Prevalence
77 II, 5. 5. 3 | CM, Paty DW, Scheinberg L, et al (1983): New diagnostic
78 II, 5. 5. 3 | Sobocki P, Pugliatti M, Lauer L, Kobelt G (2007): Estimation
79 II, 5. 5. 3 | 28.~Sundström P, Nyström L, Forsgren L (2001): Prevalence
80 II, 5. 5. 3 | Sundström P, Nyström L, Forsgren L (2001): Prevalence of multiple
81 II, 5. 5. 3 | 218.~Sundström P, Nyström L, Forsgren L (2003): Incidence (
82 II, 5. 5. 3 | Sundström P, Nyström L, Forsgren L (2003): Incidence (1988-
83 II, 5. 5. 3 | Svenningsson A, Nyström L, et al (2004): Clinical
84 II, 5. 5. 3 | multiple sclerosis in the L’Aquila district, central
85 II, 5. 5. 3 | Geneve.~Zivadinov R, Iona L, Monti-Bragadin L, et al (
86 II, 5. 5. 3 | Iona L, Monti-Bragadin L, et al (2003): The use of
87 II, 5. 5. 3 | Grigoletto F, Amaducci L, Inzitari D (2000): Parkinson’
88 II, 5. 5. 3 | Dartigues JF, Amaducci L, Lopez-Pousa S, Manubens-Bertran
89 II, 5. 5. 3 | Disord. 14:28-37.~ ~Findley L, Aujla M, Bain PG, Baker
90 II, 5. 5. 3 | Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992): The accuracy
91 II, 5. 5. 3 | Rosati G, Granieri E, Pinna L, Devoto MC (1979): The frequency
92 II, 5. 5. 3 | Rosati G, Granieri E, Pinna L, Aiello I, Tola R, De Bastiani
93 II, 5. 6. 6 | Ferraccioli G, Hazes JM, Klareskog L, Machold K, Martin-Mola
94 II, 5. 6. 6 | Thiesce A, Listrat V, Jacob L, Nakache JP, Gabriel KR,
95 II, 5. 6. 6 | 64(10):1456-61~Jacobson L. and Lindgren B (1996):
96 II, 5. 6. 6 | M101-M107~Meerding WJ, Bonneux L, Polder JJ, Koopmanschap
97 II, 5. 7. 7 | Diez Roux AV, Chambless L, Merkin SS, Arnett D, Eigenbrodt
98 II, 5. 8. 7 | Respir J 23: 402-406.~ ~Bilde L, Rud Svenning A, Dollerup
99 II, 5. 8. 7 | E, Bonnefoy X, Carrozzi L, Viegi G, Charpin D, Annesi-Maesano
100 II, 5. 8. 7 | Corsico A, Zoia MC, Carrozzi L, Cazzoletti L, Beccaria
101 II, 5. 8. 7 | Carrozzi L, Cazzoletti L, Beccaria M, Marinoni A,
102 II, 5. 8. 7 | LM, Romagnoli M, Corbetta L, Casoni G, Busljetic K,
103 II, 5. 8. 7 | Jimenez-Ruiz CA, Fernandez-Fau L, Viejo JL, Miravitlles M. (
104 II, 5. 8. 7 | 1504.~ ~Murtagh E, Heaney L, Gingles J, Shepherd R,
105 II, 5. 8. 7 | 608-14~ ~ ~Schirnhofer L, Lamprecht B, Vollmer WM,
106 II, 5. 8. 7 | F, Baldacci S, Carrozzi L, Giuntini C (2000): Prevalence
107 II, 5. 8. 7 | S, Soriano JB, Carrozzi L (2004): The proportionalVenn
108 II, 5. 9. 4 | to pet ownership (Fasce L, 2005), but may also be
109 II, 5. 9. 7 | 2002; 20:1071-1079~ ~Fasce L, Tosca MA, Silvestri M,
110 II, 5. 9. 7 | Figures, ERJ~ ~Mantovani L G, Bettoncelli G, Cricelli
111 II, 5. 10. 7 | Cornelisse-Vermaat JR, Frewer L, Mills C, AEJ Dubois (2007):
112 II, 5. 10. 7 | Hourihane JO'B, Frewer L, Knibb RC, Oude Elberink
113 II, 5. 10. 7 | Journal of the European Union L 109, 6.5.2000, pp. 29–42.~htt ~ ~
114 II, 5. 10. 7 | Journal of the European Union L 308, 25.11.2003, pp. 15–
115 II, 5. 10. 7 | Journal of the European Union L 75, 22.03.2005, pp. 33–34.~htt ~ ~
116 II, 5. 10. 7 | Journal of the European Union L 310, 28.11.2007, pp. 11–
117 II, 5. 10. 7 | Koch P, Crevel RW, Frewer L (2004): Information provision
118 II, 5. 10. 7 | Burney P, Beyer K, Frewer L, Madsen C, Botjes E, Crevel
119 II, 5. 10. 7 | C, Gislason D, Zuidmeer L, Sodergren E, Sigurdardottir
120 II, 5. 10. 7 | Fitzpatrick J, Mills C, Privalle L, Vieths S (2007): Evaluating
121 II, 5. 11. 3 | 1980s (B Larsson-Stymne and L Widström, 1985), while in
122 II, 5. 11. 3 | to be roughly around 30% (L Dotterud and E Falk, 1994).
123 II, 5. 11. 3 | during the 1985–1995 period (L Mattila et al. 2001).~ ~
124 II, 5. 11. 3 | before 20 years of age (L Dotterud and E Falk, 1994).
125 II, 5. 11. 3 | cobalt (B Larsson-Stymne and L Widström, 1985). Evidence
126 II, 5. 11. 3 | Environment, 2007;388:24-34.~L Dotterud, E Falk, Metal
127 II, 5. 11. 3 | 379–385.~B Larsson-Stymne, L Widstrom, Ear piercing–a
128 II, 5. 11. 3 | Dermatitis, 2005;52:29–35.~L Matt o, Prevalence of nickel
129 II, 5. 11. 7 | 2001.~ ~Fouere S, Adjadj L, Pawin H (2005): How patients
130 II, 5. 11. 7 | Larsson-Stymne B, Widstrom L (1985): Ear piercing – a
131 II, 5. 11. 7 | Levi F, Te VC, Randimbison L et al (2001): Trends in
132 II, 5. 11. 7 | Verboom P, Hakkaart-van Roijen L, et al (2002): The cost
133 II, 5. 11. 7 | Svensson A, Diepgen Th, Naldi L, Coenraads PJ, Elsner P,
134 II, 5. 12. 7 | Forte P,~Pisani A, Soldo L, Sarrecchia B, et al (1989):
135 II, 5. 12. 7 | 227.~ ~Shepard CW, Finelli L, Alter MJ (2005): Global
136 II, 7. 7 | Vincenten J, Brussoni M, Towner L (2006): Child Safety Good
137 II, 7. 7 | Racioppi F, Eriksson L, Tingvall C, Villaveces
138 II, 8. 2. 1 | C. Finlayson, J., Allan, L., Martin, G. and Robinson,
139 II, 8. 2. 1 | Verdugo, M-A, Wehmeyer, M.L. and Yeager, M.H. (2007).
140 II, 8. 2. 1 | Määttä, T., Salvador-Carulla, L., Garrido-Cumbrera, M.,
141 II, 8. 2. 1 | Jørgensen, F., & O’Farrell, L., (2005). Brief Research
142 II, 8. 2. 2 | Gilbert CE, Anderton L, Dandona L, Foster A. (1999):
143 II, 8. 2. 2 | CE, Anderton L, Dandona L, Foster A. (1999): Prevalence
144 II, 8. 2. 2 | Cesareo M, Corsi A and Cerulli L. (2005): Incidence of visual
145 II, 9. 1. 1 | HW, Graubard BI, Isotalo L (1993): Effect of age, parity,
146 II, 9. 1. 1 | Kramer MS, Yang H, Morin L, Fretts RC (2000): Determinants
147 II, 9. 1. 1 | 843-9.~ ~Kramer MS, Seguin L, Lydon J, Goulet L (2000b):
148 II, 9. 1. 1 | Seguin L, Lydon J, Goulet L (2000b): Socio-economic
149 II, 9. 1. 1 | en Europe: comparaison de l'experience de 9 services
150 II, 9. 1. 1 | Bakoula C, Hemminki E, Knudsen L, Levasseur M, Schenker J,
151 II, 9. 1. 1 | Van Reempts P, Gortner L, Milligan D, Cuttini M,
152 II, 9. 1. 2 | 7. References~ ~Abramsky L, Dolk H and a EUROCAT Folic
153 II, 9. 1. 2 | Portillo I, Addor M-C, Abramsky L, Ritvanen A, Robert-Gnansia
154 II, 9. 1. 2 | 402. ~Busby A, Abramsky L, Dolk H, Armstrong B and
155 II, 9. 1. 2 | Fevotte J, Kiel G, Mandereau L, for the Occupational Exposure
156 II, 9. 1. 2 | Bakker M, Gener B, Abramsky L, Addor M-C and Queisser-Luft
157 II, 9. 1. 2 | Dolk H, Stone D, Abramsky L, Alberman E, Scott JES (
158 II, 9. 2. 7 | health (2003-2008), OJ No L 271, 9 October 2002.~ ~European
159 II, 9. 2. 7 | health (2008-13), OJ No L 301, 20 November 2007.~ ~
160 II, 9. 3. 1 | 300 ng/dl (or 10.4 nmol/L) of total testosterone as
161 II, 9. 3. 1 | dl (50 pg/ml)(0.17 nmol/L).~ ~In a joint statement
162 II, 9. 3. 1 | off of 230 ng/dL (8 nmol/L) of total testosterone is
163 II, 9. 3. 1 | is > 346 ng/dL (12 nmol/L) ART is not necessary, while
164 II, 9. 3. 1 | respectively: <180 pmol/L (52 pg/ml), between 180
165 II, 9. 3. 1 | between 180 and 250 pmol/L (72 pg/ml) and > 250 pmol/
166 II, 9. 3. 1 | 72 pg/ml) and > 250 pmol/L (52 pg/ml).~ ~A complete
167 II, 9. 3. 1 | D.R. Fourcade R. Kiemeney , L, Lee C. and the UrEpik Study
168 II, 9. 3. 1 | Brownhill S, Wilhelm K, Barclay L & Schmied V (2005): 'Big
169 II, 9. 3. 1 | sti.2004.009415~ ~Forsgren L, Beghi E, Õun A, Sillanpää
170 II, 9. 3. 1 | M, Tsuboi K, Dennerstein L (2004); Prevalence of eating
171 II, 9. 3. 2 | HW, Graubard BI, Isotalo L (1993): Effect of age, parity,
172 II, 9. 3. 2 | Kramer MS, Yang H, Morin L, Fretts RC (2000): Determinants
173 II, 9. 3. 2 | 22.~ ~Kramer MS, Seguin L, Lydon J, Goulet L (2000):
174 II, 9. 3. 2 | Seguin L, Lydon J, Goulet L (2000): Socio-economic disparities
175 II, 9. 3. 2 | en Europe: comparaison de l'experience de 9 services
176 II, 9. 3. 2 | 332(7547):937-9.~ ~Le Fort L (1866) : Des maternités
177 II, 9. 3. 2 | 1866) : Des maternités de l'Europe. Paris: Masson, 1866.~ ~
178 II, 9. 3. 2 | Marret S, Ancel PY, Marpeau L, Marchand L, Pierrat V,
179 II, 9. 3. 2 | PY, Marpeau L, Marchand L, Pierrat V, Larroque B,
180 II, 9. 3. 2 | Petersburg: Imprimerie de l'Academie Imperiale des Sciences,
181 II, 9. 3. 2 | Bakoula C, Hemminki E, Knudsen L, Levasseur M, Schenker J,
182 II, 9. 3. 2 | Van Reempts P, Gortner L, Milligan D, Cuttini M,
183 II, 9. 3. 3 | Pereire ME, da Cunha Teles L (2004): HIV/AIDS risk perception,
184 II, 9. 3. 3 | Silva MO, Astin M, Wyness L, Bloemenkamp KWM, Jahn A,
185 II, 9. 3. 3 | McGarrigle CA, Østergaard L (2004): A comparison of
186 II, 9. 3. 3 | Kirby D, Laris BA, Rolleri L (2006): Impact of sex and
187 II, 9. 3. 3 | 305~Serbanescu F, Morris L, Marin M (2001): Reproductive
188 II, 9. 5. 6 | February 7 2002~ ~Doyal L A (1998): Draft Framework
189 II, 9. 5. 6 | March 2005~ ~Wang S, An L, Cochran SD (2002): Women.
190 III, 10. 1. 3 | 52-62.~Green LW, Potvin L (2004): Determinants of
191 III, 10. 1. 3 | Candeias V, Keller I, Riley L, Roy C, Tukuitonga C (2006):
192 III, 10. 1. 3 | Health 15(1):57-62.~Sher L (2006): Alcoholism and suicidal
193 III, 10. 1. 3 | Publishers; p. 205-8.~Tappy L, Binnert C, Schneiter Ph (
194 III, 10. 2. 1 | Kunze M, McNeill A, Ramström L (2003): European Union policy
195 III, 10. 2. 1 | Burns HJG, Christensen L, Denis L, Dicato M, Diehl
196 III, 10. 2. 1 | HJG, Christensen L, Denis L, Dicato M, Diehl L, Doll
197 III, 10. 2. 1 | Denis L, Dicato M, Diehl L, Doll R, Franceschi S, Gillis
198 III, 10. 2. 1 | Gillis CR, Gray N, Griciute L, Hackshaw A, Kasler M, Kogevinas
199 III, 10. 2. 1 | JJM, Crialesi R, Grötvedt L (2000): Educational differences
200 III, 10. 2. 1 | 2006; 27:517-524~ ~Joossens L, Raw M (2008): Progress
201 III, 10. 2. 1 | who had BACs between 0.2g/l and 0.49g/l had at least
202 III, 10. 2. 1 | between 0.2g/l and 0.49g/l had at least a three times
203 III, 10. 2. 1 | with a BAC between 0.5g/L and 0.79g/L and 11 times
204 III, 10. 2. 1 | between 0.5g/L and 0.79g/L and 11 times with a BAC
205 III, 10. 2. 1 | with a BAC between 0.8g/l and 0.99 g/L.~There is a
206 III, 10. 2. 1 | between 0.8g/l and 0.99 g/L.~There is a relationship
207 III, 10. 2. 1 | i.e. as low as zero or 0.2g/l in a number of countries
208 III, 10. 2. 1 | number of countries and 0.5g/l or lower in most countries
209 III, 10. 2. 1 | JW, Gruenewald PJ, Hill L, Holder HD, Homel R, Österberg
210 III, 10. 2. 1 | 02 and C-429/02.~ ~Jones L, James M, Jefferson T, Lushey
211 III, 10. 2. 1 | CE, Van Loveren C, Seppa L, Cochran JA, Polido M, Athanossouli
212 III, 10. 2. 1 | Unpublished document.~ ~Koivusilta L, Honkala S, Honkala E, Rimpelä
213 III, 10. 2. 1 | Loveren C, Fernandes B, Seppa L, Athanassouli T. Fluoride
214 III, 10. 2. 1 | 133.~ ~Maxwell K, Tucker L (1992): Effects of weight
215 III, 10. 2. 1 | Helakorpi et al, 2007; l’Institut Roche de l’Obésité,
216 III, 10. 2. 1 | 2007; l’Institut Roche de l’Obésité, 2006; Institute
217 III, 10. 2. 1 | dietary record~7~Volatier J.L. Enquête INCA Individuelle
218 III, 10. 2. 1 | findings. Steingrímsdóttir, L, Þorgeirsdóttir H, Ólafsdóttir
219 III, 10. 2. 1 | 24-hour recall~1~Szponar L., Sekula W., Nelson M.,
220 III, 10. 2. 1(24)| Helakorpi et al, 2007), France (l’Institut Roche de l’Obésité,
221 III, 10. 2. 1(24)| France (l’Institut Roche de l’Obésité, 2006), Germany (
222 III, 10. 2. 1 | 2006), France (36.3%) (l’Institut Roche de l’Obésité,
223 III, 10. 2. 1 | 3%) (l’Institut Roche de l’Obésité, 2006) and Denmark (
224 III, 10. 2. 1 | concentrations (<5.9 µg/l) in more than half (56%)
225 III, 10. 2. 1 | with very low levels (<3 µg/l) in 20%. The ENHR confirmed
226 III, 10. 2. 1 | Aranceta-Bartrina J, Serra-Majem L, Foz-Sala M, Moreno-Esteban
227 III, 10. 2. 1 | Bayingana K, Demarest S, Gisle L, Hesse E, Miermans PJ, Tafforeau
228 III, 10. 2. 1 | School Medicine (2004): L’excès de poid chez les adolescents
229 III, 10. 2. 1 | Vieira J, Carreira M, Medina L, Reis L, Galvão-Teles A (
230 III, 10. 2. 1 | Carreira M, Medina L, Reis L, Galvão-Teles A (2006):
231 III, 10. 2. 1 | Davidsen M, Hesse U, Eriksen L, Christensen AL, Grønbæk
232 III, 10. 2. 1 | C, Tudor-Smith C, Moore L (2005): Validity of self-reported
233 III, 10. 2. 1 | relevance):~Official Journal L 052 , 22/02/2001 P. 0019 –
234 III, 10. 2. 1 | relevance):~Official Journal L 083 , 22/03/2006 P. 0014 –
235 III, 10. 2. 1 | LexUriServ/LexUriServ.do?uri=OJ:L:2006:083:0014:01:EN:HTML]~ ~
236 III, 10. 2. 1 | foodstuffs. Official Journal L 109 , 06/05/2000 P. 0029 –
237 III, 10. 2. 1 | relevance):~Official Journal L 183 , 12/07/2002 P. 0051 –
238 III, 10. 2. 1 | foods. Official Journal L 404 , 30/12/2006 P. 0009 –
239 III, 10. 2. 1 | LexUriServ/LexUriServ.do?uri=OJ:L:2006:404:0009:01:EN:HTML]~
240 III, 10. 2. 1 | foods.~Official Journal L 404 , 30/12/2006 P. 0026 –
241 III, 10. 2. 1 | LexUriServ/LexUriServ.do?uri=OJ:L:2006:404:0026:01:EN:HTML].~
242 III, 10. 2. 1 | LexUriServ/LexUriServ.do?uri=OJ:L:2007:273:0001:0030:EN:PDF]~ ~
243 III, 10. 2. 1 | Kriaučionienė V, Paalanen L, Prättälä R (2007): Suaugusių
244 III, 10. 2. 1 | accessed on 8 October 2007).~ ~l'Institut Roche de l'Obésité (
245 III, 10. 2. 1 | l'Institut Roche de l'Obésité (2006): ObEpi-Roche
246 III, 10. 2. 1 | épidémiologique nationale sur l'obésité et le surpoids en
247 III, 10. 2. 1 | communication):]. Paris, l'Institut Roche de l'Obésité (
248 III, 10. 2. 1 | Paris, l'Institut Roche de l'Obésité (in French).~ ~Institute
249 III, 10. 2. 1 | Kaklamanou M, Loannidis L, Lanaras L, Kaklamanos L (
250 III, 10. 2. 1 | M, Loannidis L, Lanaras L, Kaklamanos L (2004): First
251 III, 10. 2. 1 | L, Lanaras L, Kaklamanos L (2004): First national epidemiological
252 III, 10. 2. 1 | S, Kaklamanou M, Lanaras L, Kaklamanos I (2006): First
253 III, 10. 2. 1 | 542.~ ~Lobstein T, Baur L, Uauy R, for the IASO International
254 III, 10. 2. 1 | Martínez-Hernández A, Enríquez L, Moreno-Moreno MJ, Martí
255 III, 10. 2. 1 | S, Helasoja V, Paalanen L, Prättälä R (2005): Latvijas
256 III, 10. 2. 1 | 2008).~ ~Rodler I, Bíró L, Greiner F, Zajkás G, Szórád
257 III, 10. 2. 1 | 1259-1265.~ ~Serra Majem L, Ribas Barba L, Aranceta
258 III, 10. 2. 1 | Serra Majem L, Ribas Barba L, Aranceta Bartrina J, Pérez
259 III, 10. 2. 1 | Santana P, Peña Quintana L (2003): Obesidad infantil
260 III, 10. 2. 1 | Gynecology 104:720–726.~ ~Szponar L, Rychlik E, Oltarzewski
261 III, 10. 2. 1 | survey]. (Edited by Szponar L, Sekula W, Rychlik E, Oltarzewski
262 III, 10. 2. 1 | Aviles M, Shetty P, Daniels L (1998): Effectiveness of
263 III, 10. 2. 1 | Press.~ ~Zaletel-Kragelj L, Eržen I, Fras Z (2004):
264 III, 10. 2. 1 | 1259-1271.~ ~Keinan-Boker L, Peeters PH, Mulligan AA,
265 III, 10. 2. 1 | Linseisen J, Bergstrom E, Gafa L, Gonzalez CA, Thiebaut A,
266 III, 10. 2. 1 | Morote Gomez P, Janzon L, Stattin P, Welch AA, Spencer
267 III, 10. 2. 1 | Mattisson I, Weinehall L, Riboli E, Slimani N (2002):
268 III, 10. 2. 1 | Rodriguez M, Lasheras C, Janzon L, Jansson J, Luben R, Spencer
269 III, 10. 2. 2 | cholesterol less than 3-4 mmol/l (~ 115-155 mg/dl).~ ~Various
270 III, 10. 2. 2 | healthy is below 5 mmol/l (~ 190 mg/dl). High Density
271 III, 10. 2. 2 | HDL less than 1.2 mmol/l (~ 40-45 mg/dl) is considered
272 III, 10. 2. 4 | A., Gesteland R, Walters L (1998): New Goals for the
273 III, 10. 2. 4 | Kononen J, Bubendorf L, Kallioniemi A, Barlund
274 III, 10. 2. 5 | 2005;353:1802-909.~ ~Bastra L, Hadders-Algra M, Neeleman
275 III, 10. 3. 1 | Hakama M, Heid I, Kreienbrock L, Kreuzer M, Lagarde F, Mäkeläinen
276 III, 10. 3. 1 | Rosario A, Tirmarche M, Tomáek L, Whitley E, Wichmann HE,
277 III, 10. 3. 1 | Egan Km, Titus-Ernstoff L, Anderson Ha, Trentham-Dietz
278 III, 10. 3. 2 | average between 1 and 11 ng/l for Pt with high peaks up
279 III, 10. 3. 2 | with high peaks up to 44 ng/l in most sampling stations
280 III, 10. 3. 2 | 199-208.~ ~Ravindra, K, L Bencs, R van Grieken (2004):
281 III, 10. 4. 2(28)| Directive 79/700/EEC (OJ L 187, 16.7.2002, p 30)~
282 III, 10. 4. 2(29)| Directive 92/117/EEC(OJ L 325,12.12.2003 p. 31)~
283 III, 10. 4. 2(31)| OJ L 224, 18.8.1990, p.19~
284 III, 10. 4. 2(33)| diseases in the Community (OJ L 268, 3.10.1998,p.1)~
285 III, 10. 4. 2 | concentrations of 598ng/L have been found in drinking
286 III, 10. 4. 2(35)| residues in and on cereals (OJ L 221, 7.8.1986, p 37).~
287 III, 10. 4. 2(36)| foodstuffs of animal origin (OJ L 221, 7.8.1986, p 43).~
288 III, 10. 4. 2(37)| fruit and vegetables (OJ L 350,14.12.1986, p 71).~
289 III, 10. 4. 2(41)| Journal of the European Union l 160/98~
290 III, 10. 4. 2 | European Communities No. L 31/1, 1 February2002. Available
291 III, 10. 4. 2 | European Communities No. L 338, 22 December 2005. Available
292 III, 10. 4. 2 | European Communities No. L 043, 14 February 1997. Available
293 III, 10. 4. 2 | European Communities No. L 117, 8 May 1990. Available
294 III, 10. 4. 2 | European Communities No. L 106 , 17 April 2001. Available
295 III, 10. 4. 2 | European Communities No. L 268/1, 18 October 2003.
296 III, 10. 4. 2 | European Communities No. L 287/1, 5 November 2003.
297 III, 10. 4. 2 | European Communities No. L 268/24, 18 October 2003.
298 III, 10. 4. 2 | European Communities No. L 109, 6 May 2000. Available
299 III, 10. 4. 2 | European Communities No. L 12/3, 18 January 2007 Available
300 III, 10. 4. 2 | European Communities No. L 404/26, 30 December 2006.
301 III, 10. 4. 2 | European Communities No. L 183/51, 12 July 2002. Available
302 III, 10. 4. 2 | European Communities No. L 52/19, 22 February 2001.
303 III, 10. 4. 2 | European Communities No. L 83/14, 22 March 2006.~Available
304 III, 10. 4. 2 | European Communities No. L 165, 30 April 2004. Available
305 III, 10. 4. 2 | European Communities No. L 395, 30 December 1989.~ ~
306 III, 10. 4. 2 | European Communities No. L 24, 30 January 1998, 31-
307 III, 10. 4. 2 | European Communities No. L 139, 30 April 2004.~ ~European
308 III, 10. 4. 2 | European Communities No. L 139, 30 April 2004.~ ~European
309 III, 10. 4. 2 | European Communities No. L 332, 30 December 1995.~ ~
310 III, 10. 4. 2 | vegetables. Official Journal L 350 , 14/12/1990. Available
311 III, 10. 4. 3 | maximum concentration of 10 μg/l for As in drinking water .
312 III, 10. 4. 3 | Vahter et al, 2006). At 50 μg/l the risk 1/100 which is
313 III, 10. 4. 3 | water are exceeding 10 μg/l and occasionally reach 25
314 III, 10. 4. 3 | occasionally reach 25 μg/l.~ ~Access to safe drinking-water~ ~
315 III, 10. 4. 3 | drinking water, i.e. 10 μg/l (10 ppb).~ ~The Drinking
316 III, 10. 5. 1 | European Communities, 1998, L 330(41):32 Available at:
317 III, 10. 5. 1 | LexUriServ/site/en/oj/1998/l_330/l_33019981205en00320054.
318 III, 10. 5. 1 | LexUriServ/site/en/oj/1998/l_330/l_33019981205en00320054.pdf,
319 III, 10. 5. 1 | Biology.~Konlaan, B B. Bygren, L O. Johansson, S E. Visiting
320 III, 10. 5. 1 | Z, Sebastian A, Larsson L, Wang Z, Zhang Z, Norbäck
321 III, 10. 5. 1 | Santé pour les Régions de l'Europe~LHHAP~Local Housing
322 III, 10. 6. 2 | 6. References~ ~Berkman, L. & Glass, T. (2000). Social
323 III, 10. 6. 2 | support, and health. In L.Berkman & I. Kawachi (Eds.),
324 IV, 11. 6. 5 | Castoro C, Bertinato L et al. (2007): Day surgery:
325 IV, 11. 6. 5 | Sons, Ltd.~ ~Gundersen L (2000): "The Effect of Clinical
326 IV, 11. 6. 5 | Press.~ ~Lesar TS, Briceland L et al. (1997): "Factors
327 IV, 11. 6. 5 | Europe: 53.~ ~Siciliani L, Hurst J (2004): Explaining
328 IV, 11. 6. 5 | 145-50.~ ~Starfield B, Shi L et al. (2005): "The Effects
329 IV, 11. 6. 5 | Lancet 369: 698-700~ ~Vagac L, Haulikova L (2003): Study
330 IV, 11. 6. 5 | 700~ ~Vagac L, Haulikova L (2003): Study on the Social
331 IV, 11. 6. 5 | Assessment 1(Doc09).~ ~Kane, R. L. (1997). Understanding Health
332 IV, 12. 2 | is as low as zero or 0.2g/l in a number of countries,
333 IV, 12. 2 | number of countries, and 0.5g/l or lower in most countries
334 IV, 13. 9 | Rigby M, Köhler L (editors) (2002): Child
|
|
| |
